Análisis de la acción InspireMD Inc (NSPR)

Análisis de IA of InspireMD Inc (NSPR)

Comprar

InspireMD Inc (NSPR) presents a compelling buying opportunity at the current price of $0.6972, especially considering its recent 5-day price surge of 54.93% and a strong RSI of 66.707, indicating bullish momentum. The company has shown significant revenue growth of over 120% year-over-year in Q1 2026, despite facing regulatory challenges, which reflects its potential for recovery and growth. However, the main risk lies in the company's ongoing financial struggles, as evidenced by a forward P/E ratio of 11.6959 and a net income loss of $14,324,000 in Q2 2026, which could impact future profitability. Overall, the positive catalysts from FDA approvals and strong recent performance outweigh the risks, making it a favorable buy at this time.

Métricas de valoración

El PER previsto actual de InspireMD Inc (NSPR) es 11.70, frente a su media de 5 años de 0.18.

PER previsto

Muy sobrevalorado

Media 5A P/E

0.18

P/E actual

11.70

Sobrevalorada

5.47

Infravalorada

-5.10

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-0.52

EV/EBITDA actual

-0.10

Sobrevalorada

0.11

Infravalorada

-1.14

Precio/ventas previsto

Infravalorado

Media 5A P/S

5.05

P/S actual

1.48

Sobrevalorada

8.45

Infravalorada

1.65

Escenarios de precio de Alphio AI para NSPR

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NSPR

$2.97

Precio del escenario

B

Base

Base · 50%NSPR

$2.53

Precio del escenario

B

Bajista

Bajista · 25%NSPR

$2.25

Precio del escenario

Preguntas frecuentes sobre NSPR, respondidas por Alphio AI

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InspireMD Inc (NSPR) presents a compelling buying opportunity at the current price of $0.6972, especially considering its recent 5-day price surge of 54.93% and a strong RSI of 66.707, indicating bullish momentum. The company has shown significant revenue growth of over 120% year-over-year in Q1 2026, despite facing regulatory challenges, which reflects its potential for recovery and growth. However, the main risk lies in the company's ongoing financial struggles, as evidenced by a forward P/E ratio of 11.6959 and a net income loss of $14,324,000 in Q2 2026, which could impact future profitability. Overall, the positive catalysts from FDA approvals and strong recent performance outweigh the risks, making it a favorable buy at this time.